CD274 and neoplasm: Immune checkpoint inhibitors target programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) on the host T cells or programmed death ligand-1 (PD-L1) on the tumor cells, which brings about the activation of T cells.